Juno Therapeutics Breaking News Potential Treatment Target Genes Found in Genomic Study of Bipolar Disorder Ontario Brain Institute, EpiSign Partner on Rare Genetic Disorder Diagnosis Oncocyte Q4 Revenue Surges on Pharma Services as Firm Readies Transplant Test Kit for FDA Lucid Diagnostics Q4 Revenues Rise 20 Percent Congenital Heart Disease Contributors Identified in Sequenced Pediatric Cohorts
